NEW YORK (TheStreet) -- Shares of Baxter International (BAX) - Get Report are up by 2.95% to $38.38 in pre-market trading on Tuesday after the company reported its 2015 fourth quarter earnings results.

Before the market open today, the Deerfield, IL-based healthcare company reported earnings of 37 cents per diluted share, which beat analysts' expectations of 32 cents per share.

Revenue for the quarter was $2.6 billion, higher than analysts' estimates of $2.54 billion.

''Our fourth quarter performance clearly reflects the positive impact of our initial post-spin margin expansion programs, and we continue to build upon the momentum that has been established across the organization,'' Chairman and CEO José Almeida said in a statement on Tuesday morning.

In June, the company announced its spin off from its biopharmaceutical business Baxalta (BXLT).

Baxter focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute medical conditions.

Separately, TheStreet Ratings Team has a "Buy" rating with a score of B on the stock.

This is driven by multiple strengths, which should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks covered by the team.

The company's strengths can be seen in multiple areas, such as its solid stock price performance, reasonable valuation levels, notable return on equity and expanding profit margins.

The team believes its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share.

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

You can view the full analysis from the report here: BAX

Image placeholder title


data by